Equity · Healthcare
VRTX
NASDAQVertex Pharmaceuticals (VRTX)
The line runs 547.71 USD on 24 August through 514.99 USD on 20 November, on a scale from 475 to 575. Days the market did not trade hold the previous close, flat.
- Market cap
- 130.6B USD
- P/E (TTM)
- 33.2
- Revenue, year to Dec 2025
- 12.0B USD
- EPS, diluted, year to Dec 2025
- 15.32 USD
- 52-week range
- 421.03 USD – 569.99 USD
- Avg volume
- 85.5K
- Mentions, 30 days
- 14
- Net sentiment
- +0.09
as of Nov 20, 2026
Have Vertex Pharmaceuticals (VRTX) insiders bought or sold shares recently?
In the 90 days to 22 Nov 2026, Vertex Pharmaceuticals insiders reported 4 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 13 Feb 2026, show no open-market purchase.
Form 4, 90 days to 22 Nov 2026, newest reported trade 16 Nov 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 16 Nov 2026 | Bhatia Sangeeta N.Director | Sell | 271 | 148K USD |
| 16 Nov 2026 | Thornberry NancyDirector | Sell | 1,000 | 548K USD |
| 12 Nov 2026 | WAGNER CHARLES F JREVP, CO & FO | Sell | 15,286 | 8.4M USD |
| 06 Nov 2026 | Kewalramani ReshmaCEO & President | Sell | 11,866 | 6.3M USD |
| Sold | 4 open-market sales | 28,423 | $15.38M |
4 other filings in the window: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 20 Oct 2026 | Brennan Daniel J.Director | Award | 795 | 400K USD |
| 08 Sep 2026 | van Grunsven JasperEVP, CP and NPPO | Award | 8,682 | |
| 28 Aug 2026 | Ambrose KristenSVP & Chief Accounting Officer | Award | 5,000 | |
| 27 Aug 2026 | SACHS BRUCE IDirector | Gift | 6,000 |
Which funds hold Vertex Pharmaceuticals (VRTX)?
12 of the 45 institutional funds we track reported a Vertex Pharmaceuticals position for the quarter ended 30 Sep 2026 — a combined 1.9B USD; the latest of those filings landed 16 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Citadel Advisors | Added | 1,032,674 | 539.9M USD | +102.3% |
| Millennium Management | Held (±25%) | 567,655 | 296.8M USD | +21.2% |
| AQR Capital Management | Held (±25%) | 499,767 | 261.3M USD | −18.9% |
| Marshall Wace | Held (±25%) | 412,702 | 215.8M USD | −24.1% |
| Renaissance Technologies | Held (±25%) | 396,768 | 207.4M USD | +24.0% |
| Balyasny Asset Management | Added | 230,771 | 120.6M USD | +59.1% |
| Two Sigma Investments | Trimmed | 203,123 | 106.2M USD | −28.7% |
| Man Group | Held (±25%) | 132,607 | 69.3M USD | −4.8% |
| Bridgewater Associates | Added | 34,915 | 18.3M USD | +221.4% |
| Fisher Asset Management | Held (±25%) | 28,676 | 15.0M USD | +17.2% |
Showing the 10 largest of 12 reported positions. The figures above count all of them.
Have members of Congress traded Vertex Pharmaceuticals (VRTX)?
The most recent congressional trade disclosed in Vertex Pharmaceuticals is a purchase by David J. Taylor (house, OH), dated 07 Aug 2025.
STOCK Act disclosures
| Traded | Member | Type | Amount | Filed after |
|---|---|---|---|---|
| 07 Aug 2025 | David J. Taylorhouse · Republican–OH | Purchase | 1K USD–15K USD | 26 days |
| 11 Jun 2025 | Lisa C. McClainhouse · Republican–MI | Sale | 1K USD–15K USD | 63 days |
| 10 Jun 2025 | Lisa C. McClainhouse · Republican–MI | Sale | 1K USD–15K USD | 64 days |
| 12 May 2025 | Jefferson Shrevehouse · Republican–IN | Sale | 15K USD–50K USD | 41 days |
| 20 Mar 2025 | Byron Donaldshouse · Republican–FL | Sale | 1K USD–15K USD | 25 days |
| 24 Feb 2025 | Jefferson Shrevehouse · Republican–IN | Purchase | 15K USD–50K USD | 13 days |
| 11 Dec 2024 | Lisa C. McClainhouse · Republican–MI | Purchase | 1K USD–15K USD | 245 days |
| 24 Oct 2023 | Greg Stantonhouse · Democrat–AZ | Sale | 1K USD–15K USD | 16 days |
What has been filed or recorded for Vertex Pharmaceuticals (VRTX)?
The filings we hold for Vertex Pharmaceuticals, newest first: 6 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 29 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 29 Oct 2026 | Fails to deliver | Shares failed to deliver | 1 shares | 530 USD notional · <0.001% of shares out |
| 28 Oct 2026 | Fails to deliver | Shares failed to deliver | 5 shares | 3K USD notional · <0.001% of shares out |
| 27 Oct 2026 | Fails to deliver | Shares failed to deliver | 15 shares | 8K USD notional · <0.001% of shares out |
| 14 Oct 2026 | Fails to deliver | Shares failed to deliver | 424 shares | 206K USD notional · <0.001% of shares out |
| 13 Oct 2026 | Fails to deliver | Shares failed to deliver | 919 shares | 466K USD notional · <0.001% of shares out |
| 09 Oct 2026 | Fails to deliver | Shares failed to deliver | 46 shares | 23K USD notional · <0.001% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS 2.56 USD | |
| 30 Sep 2026 | Financials | Total assets | 32.7B USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 20.9B USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS 4.31 USD | |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS 4.02 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS 15.32 USD | |
| 31 Dec 2025 | Financials | Revenue | 12.0B USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | 4.0B USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | 15.32 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS 4.20 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS 3.99 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS 2.49 USD | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −2.08 USD |
What is Reddit saying about Vertex Pharmaceuticals (VRTX)?
Reddit mentioned VRTX 14 times in the 30 days to 21 November 2026, across 3 of the communities we track. All of them were scored for sentiment: 64% read bullish, 0% bearish and 36% neither. Reddit data updated 21 November 2026.
30-day window, Method
How do Reddit mentions of Vertex Pharmaceuticals (VRTX) compare with its price?
Share ↗
Which subreddits are talking about Vertex Pharmaceuticals (VRTX)?
30 days
| Community | Share | Mentions | Net sentiment |
|---|---|---|---|
| r/wallstreetbets | 57% | 8 | +0.07 |
| r/stocks | 29% | 4 | +0.09 |
| r/investing | 14% | 2 | +0.15 |
Which names move with Vertex Pharmaceuticals (VRTX) on Reddit?
BMWYY moved most closely with Vertex Pharmaceuticals (VRTX): when the crowd talked about one, it talked about the other (+0.67 over 31 days). Co-discussion, not price.
BMWYY | Palm OIL | SQ | ||||
|---|---|---|---|---|---|---|
VRTX | +0.67 | +0.65 | +0.64 | +0.62 | +0.61 | +0.61 |
View the matrix as a tableHide the table
| Pair | Match | Days measured |
|---|---|---|
| VRTX and BMWYY | +0.67 | 31 days |
| VRTX and FTW | +0.65 | 31 days |
| VRTX and Palm OIL | +0.64 | 31 days |
| VRTX and FHB | +0.62 | 31 days |
| VRTX and Barc.l | +0.61 | 31 days |
| VRTX and SQ | +0.61 | 31 days |
What do people ask about Vertex Pharmaceuticals (VRTX)?
What did Vertex Pharmaceuticals shares close at?514.99
Vertex Pharmaceuticals closed at 514.99 USD on 20 Nov 2026, down 1.07% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Vertex Pharmaceuticals’ market cap?130.6B
Vertex Pharmaceuticals is worth 130.6B USD by market value as of 20 Nov 2026, which is the share price times the shares on issue from its SEC filings.
What is Vertex Pharmaceuticals’ P/E ratio?33.2
Vertex Pharmaceuticals has a price-to-earnings ratio of 33.2, as of 20 Nov 2026: the share price divided by what the company earned per share over the last four reported quarters. A higher number means the market pays more for each dollar of earnings.
What is Vertex Pharmaceuticals’ revenue?12.0B
Vertex Pharmaceuticals reported revenue of 12.0B USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Vertex Pharmaceuticals insiders bought or sold shares recently?4 sales
In the 90 days to 22 Nov 2026, Vertex Pharmaceuticals insiders reported 4 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 13 Feb 2026, show no open-market purchase. A further 4 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders
Which funds own Vertex Pharmaceuticals?12 of 45
12 of the 45 funds we track reported a Vertex Pharmaceuticals position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Citadel Advisors, Millennium Management and AQR Capital Management. See Funds
Have members of Congress traded Vertex Pharmaceuticals?15 trades
Yes. 15 trades in Vertex Pharmaceuticals appear in the congressional disclosures we hold; the latest is a purchase by David J. Taylor (House, OH) dated 7 Aug 2025, filed 2 Sep 2025. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress
When did Vertex Pharmaceuticals last report earnings?2.56
Vertex Pharmaceuticals last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of 2.56 USD; no next date is announced in SEC filings yet. See Filings
What is Reddit saying about Vertex Pharmaceuticals?2 mentions
Vertex Pharmaceuticals was mentioned 2 times in the last 7 days across the finance subreddits we track, and 14 times over the trailing 30 days. Of the 14 mentions scored for sentiment, 64% read bullish and 0% bearish. That is a social signal, not investment advice. See Reddit

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- RedditReddit ingest across the tracked finance subreddits
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- Wikimedia CommonsPortraits via Wikimedia Commons. Lisa C. McClain: Office of Congresswoman Lisa McClain, Public domain; Byron Donalds: United States Congress, Public domain; Jefferson Shreve: House Creative Services, Public domain; David J. Taylor: Ike Hayman, House Creative Services, Public domain; Greg Stanton: United States Congress, Public domain.
- House disclosuresU.S. House of Representatives financial disclosures
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings
- SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words